Neurocrine Biosciences Inc.

03/28/2024 | Press release | Distributed by Public on 03/28/2024 06:31

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults